Reagena is a Finnish company that specializes in the development and manufacturing of diagnostic tests for various diseases, particularly zoonotic infections such as hantaviruses and tick-borne diseases like Lyme borreliosis and tick-borne encephalitis (TBE). The company's product range includes rapid and EIA (enzyme-linked immunosorbent assay) tests for detecting specific antibodies in human serum and plasma, which are used to diagnose diseases such as hemorrhagic fever with renal syndrome and neuroborreliosis. Reagena's tests are designed for professional use and are available for purchase through their online store, serving healthcare units, industry, and pharmacies. The company focuses on providing diagnostic solutions that help shorten the treatment path for patients and reduce the burden on healthcare.

Reagena is a Finnish in vitro diagnostics Company dedicated to developing and manufacturing rapid diagnostic solutions for zoonotic infectious diseases. As an undisputed leader in Hantavirus rapid diagnostics and a recognized pioneer in tick-borne disease testing, Reagena's portfolio spans Puumala and Dobrava/Hantaan virus serology, Lyme Borreliosis, Lyme neuroborreliosis and Tick-borne encephalitis. Serving healthcare professionals across international markets — with a presence at leading congresses such as ESCMID and Medica — Reagena's mission is to optimize patient care pathways while reducing the burden on healthcare systems. Reagena is also a trusted distributor of high quality products.

1987